XXXX and @entity4531 in @entity3520 : a controlled study.

@entity1 @entity308 @entity3520 @entity6389 @entity191 @entity29144 @entity158 @entity9663 @entity3519 @entity21 @entity4531 @entity121 @entity25 @entity8599
@entity25 are common in @entity191 and other @entity21 , @entity25 in @entity3519 is limited to generalized forms or Segawa disease. Although many @entity1 with @entity3520 ( @entity6389 ) and @entity9663 ( @entity9663 ) report poor sleep, there are no data on frequency or interactions with well known symptoms like @entity308 and @entity158 . Standardized interviews and assessment instruments, clinical examinations, and self rating forms were applied in 221 @entity1 with @entity6389 and @entity9663 , and in 93 neurologically healthy controls. @entity25 was found in 44% of @entity6389 @entity1 , 46% of @entity9663 @entity1 , and 20% of controls. In @entity3519 , it was associated with symptoms of @entity308 (frequency of 26%; p  <  0.001) and @entity4531 ( @entity4531 ) (frequency of 19%; p  <  0.01). @entity8599 (in @entity6389 ; p  <  0.05), and female sex (in @entity9663 ; p  <  0.001) were identified as further risk factors, but not severity of @entity3520 . Excessive @entity25 was rare in @entity6389 and @entity9663 (6%). With a frequency of 45%, @entity25 is common in focal @entity3519 and associated with symptoms of @entity308 , @entity8599 , and @entity4531 . Results in @entity6389 and @entity9663 @entity1 are similar, pointing to an intrinsic mechanism of @entity25 rather than a direct effect of @entity121 . Further studies on @entity29144 , including polysomnographic recordings, are warranted.
